One study developed off-the-shelf, allogeneic NK cells engineered with a FLT3-specific CAR and secreting soluble interleukin-15 (IL-15), demonstrating enhanced cytotoxicity and interferon-gamma secretion against FLT3+ AML cell lines compared to NK cells lacking the CAR or IL-15 secretion (89). This evidence concerns the gene FLT3 and acute myeloid leukemia.